Evaluation of Injectable Sustained Release Progestin Formulations for Suppression of Estrus and Ovulation in Mares

Thirty-one mares were used in an experiment to evaluate the effectiveness of three sustained-release injectable formulations of altrenogest and one formulation of medroxyprogesterone acetate (MPA) for long-term suppression of estrus and ovulation. Luteolysis was induced by injection of prostaglandin-F_2α (Lutalyse) on day 0 (6th day after the previous ovulation) and was immediately followed by treatment with 1) no injection (controls; n = 7), 2) 1.5 mL of an altrenogest solution in sustained-release vehicle (LA 150, 1.5 mL; 225 mg altrenogest; n = 6), 3) 3 mL (450 mg altrenogest) of the same solution (n = 6), 4) 500 mg altrenogest in lactide-glycolide microparticles suspended in 7-mL vehicle (MP 500; n = 6), or 5) 1.0 g MPA as a 5-mL suspension. Mares were checked for estrus daily, and their ovaries scanned every other day until a 25-mm or greater follicle was detected, after which they were scanned daily. Control mares returned to estrus an average of 3.9 days after Lutalyse administration; all the single-injection altrenogest formulations increased (P < .05) the days to return to estrus, with the greatest increase occurring in mares receiving MP 500. Return to estrus was not affected by MPA treatment. Time of ovulation was determined by serial ultrasound scans and confirmed by daily plasma luteinizing hormone (LH) and progesterone concentrations. Control mares ovulated an average of 8.8 days after Lutalyse administration. Treatment with 1.5 or 3 mL of LA 150 increased (P < .05) the mean days to ovulation to 16.5 and 21.2 days, respectively; MP 500 increased (P < .05) the days to ovulation to 33.5 days. Administration of MPA did not affect (P > .1) days to ovulation relative to control mares. The MP 500 treatment provided long-term suppression of estrus and ovulation and could prove useful for that purpose. Treatment with the LA 150 solutions provided shorter-term suppression, and a relatively tight grouping of the individual mares around the mean days to ovulation; these one-shot formulations could be useful for synchronizing ovulation in cyclic mares and inducing normal estrous cyclicity in vernal transitional mares exhibiting erratic, anovulatory estrous periods.     

Effect of Chronic Administration of Oxytocin on Corpus Luteum Function in Cycling Mares

The objective of this study was to determine if intramuscular administration of 60 units of oxytocin once daily for 29 days, regardless of when treatment was initiated during the estrous cycle (i.e., without monitoring estrous behavior and/or detecting ovulation), would induce prolonged corpus luteum (CL) function in cycling mares. Mares were randomly assigned to two groups: (1) saline-treated control (n = 7) and (2) oxytocin-treated (n = 9) subjects. Control mares received 3 cc of saline, and oxytocin-treated mares received 60 units (3 cc) of oxytocin intramuscularly for 29 consecutive days. Treatment was initiated in all mares on the same day (day 1), independent of the day of the cycle. Jugular blood samples for determination of progesterone concentration were collected three times weekly (M, W, and F) for 21 days before treatment was initiated to confirm that all mares had a luteal phase of normal duration immediately before treatment. Beginning on the first day of treatment, blood samples were collected daily for eight days and then three times weekly through day 80. Mares were considered to have prolonged CL function if serum progesterone remained >1.0 ng/mL continuously for at least 25 days after the end of the treatment period. The proportion of mares with prolonged CL function was higher in the oxytocin-treated group than in the saline-treated group (7/9 vs. 1/7, respectively; P < .05). Three of the seven oxytocin-treated mares that developed prolonged CL function initially underwent luteolysis within 4–7 days of the start of oxytocin treatment and then developed prolonged CL function after the subsequent ovulation during the treatment period. In the other four oxytocin-treated mares that developed prolonged CL function, progesterone remained >1.0 ng/mL throughout the treatment period and into the post-treatment period. All mares with prolonged CL function maintained elevated progesterone concentrations through at least day 55 of the study. In conclusion, intramuscular administration of 60 units of oxytocin for 29 consecutive days effectively prolonged CL function in mares, regardless of when treatment was initiated during the estrous cycle. Importantly, this represents a protocol for using oxytocin treatment to prolong CL function that does not require detection of estrous behavior or day of ovulation.     

Efficacy of Acupuncture Sites for Delivery of Agents to Control Estrus and Ovulation in Mares

This study was designed to determine if prostaglandin F₂α (PGF₂α) when administered on d 6 post-ovulation in a low dose in the lumbosacral space (LSS) would induce luteolysis while minimizing side effects usually associated with intramuscular administration of this analogue in mares. A second objective was to determine if human chorionic gonadotropin (hCG) injected into the LSS would reduce time to ovulation in the mare. Ten normally cycling mares served as their own controls in a crossover design, receiving intramuscular injections of PGF₂α(10 mg), intravenous injections of hCG (3000 IU) and injections of PGF and hCG at the acupuncture site (2 mg and 3000 IU, respectively), as well as sham injections of saline. Beginning 12 h after injection, mean progesterone concentrations were less (P<0.05) in PGF₂α-treated mares than in mares receiving saline. Moreover, progesterone concentrations were similar (P<0.001) between both groups of mares receiving PGF₂α. In addition, there was no difference (P>0.1) between mares receiving the acupuncture injection of PGF₂α and the intramuscular injection in days to ovulation. However, duration and severity of side effects associated with PGF₂α administration were dramatically decreased (P<0.01) when PGF₂α was delivered to the acupuncture site compared to intramuscular delivery. The time to ovulation was similar (P>0.1) for mares receiving shams, or hCG. These data indicate that delivery of 2 mg of PGF₂α in the LSS induces luteolysis and reduces the sweating and muscle cramping associated with PGF₂α administration. There was no advantage to the delivery of hCG in the LSS.     

Efficacy of Long-Acting Formulations of Estradiol or Progesterone Plus Estradiol on Estrous Synchronization in Broodmares

A preliminary trial was performed to evaluate the ability of sustained release preparations of estradiol-17β or progesterone plus estradiol-17β to synchronize estrus in cyclic mares. Group 1 mares were treated with a 50 mg intramuscular (IM) injection of sustained release estradiol-17β, while group 2 mares were treated with estradiol plus 1.5 g of sustained release progesterone. All mares received an IM injection of 10 mg of prostaglandin-F₂α (PGF₂α) 10 days after steroid treatment. Mares were examined by transrectal ultrasonography on Days 1 and 10 of treatment and then at ≤2 day intervals to monitor follicle size. Once a follicle ≥30 mm diameter and uterine edema were detected, 0.5 mg of the GnRH analog histrelin was administered IM. Mares were examined daily thereafter to detect ovulation. Group 1 mares did not exhibit ovulation synchrony (ovulations occurred 12-22 days after steroid treatment), whereas ovulation synchrony was satisfactory in group 2 mares (interval to ovulation being 20.4 ± 1.5 days, range 17-22 days). Using sustained release preparations of progesterone plus estradiol-17β, with PGF₂α administered on Day 10, could eliminate the need for daily injections of steroid preparations in oil when synchronizing estrus and ovulation.     

Effect of a Nonsurgical Embryo Transfer Procedure and/or Altrenogest Therapy on Endogenous Progesterone Concentration in Mares

Endogenous progesterone levels may decline after transcervical embryo transfer in some mares. Progestogen therapy is commonly used to support endogenous progesterone levels in embryo transfer recipient mares or those carrying their own pregnancy. The goal of this study was to determine the effects of the transcervical transfer procedure and/or altrenogest therapy on luteal function in mares. Mares were assigned to one of six treatment groups: group 1 (untreated control; n = 7 cycles), group 2 (sham transfer, no altrenogest; n = 8 cycles), group 3 (sham transfer plus altrenogest; n = 8 cycles), group 4 (pregnant, no altrenogest; n = 9 mares), group 5 (pregnant plus altrenogest; n = 9 mares), and group 6 (nonpregnant plus altrenogest; n = 10 cycles). Mares in groups 4-6 were bred and allowed an opportunity to carry their own pregnancy. Blood samples were collected for 22 days beginning on the day of ovulation. Sham embryo transfer (groups 2 and 3, combined) did not result in a decline in endogenous progesterone levels compared with control mares (group 6). However, sham embryo transfer did result in luteolysis and an abrupt decline in endogenous progesterone levels in one of the 16 (6.2%) sham-transferred mares. Altrenogest therapy in sham-transferred mares (group 3) was associated with lower endogenous progesterone levels on days 10, 12, and 13 postovulation when compared with sham-transferred mares that did not receive altrenogest (group 2). Administration of altrenogest to pregnant mares (group 5) was associated with lower concentrations of endogenous progesterone from days 14 to 18 and on day 21 compared with endogenous progesterone levels in pregnant mares not administered altrenogest (group 4). In conclusion, a transcervical embryo transfer procedure can cause luteolysis in a low percentage of mares. Altrenogest therapy may be associated with a reduction in endogenous progesterone secretion, presumably mediated by a reduction in pituitary luteinizing hormone (LH) release and a decrease in luteotropic support.     

Comparative Efficacy of Histrelin Acetate and hCG for Inducing Ovulation in Brazilian Northeastern Jennies (Equus africanus asinus)

The goal of this study was to compare the efficiency of histrelin acetate (GnRH analog) and human chorionic gonadotropin (hCG) to hasten ovulation in Brazilian Northeastern jennies (Equus africanus asinus). Thirty cycles of ten jennies were randomly assigned in one of the three groups: G0 (control group), saline; G1, 250 μg of histrelin acetate; G2, 2500 IU of hCG. Jennies were evaluated by transrectal palpation and ultrasonography, and had the administration of an ovulation-inducing agent when a follicle measuring between 29 and 32 mm of diameter was diagnosed. Jennies were monitored every 6 hours by transrectal ultrasonography until ovulation. The interval between prostaglandin administration and ovulation was lower (P < .05) in jennies from the G1 (145.2 ± 34.6 hours) and G2 (147.4 ± 27.3 hours) groups compared with the control cycle (220.0 ± 41.8 hours). Both treatments (G1, 41.15 ± 3.5 hours; G2, 37.8 ± 2.5 hours) also reduced (P < .05) the interval that jennies took to ovulate after the administration of the ovulation-inducing agent compared with the control (81.8 ± 28.8 hours). All jennies from G1 and G2 ovulated up to 48 hours after ovulation induction, whereas 100% of jennies in the control cycle ovulated later (>48 hours from the administration of saline). In conclusion, both histrelin acetate and hCG at the used dose are efficient ovulation-inducing agents in jennies promoting ovulation up to 48 hours after administration.     

Effect of eFSH on Ovarian Cyclicity and Embryo Production of Mares in Spring Transitional Phase

The use of equine FSH (eFSH) for inducing follicular development and ovulation in transitional mares was evaluated. Twenty-seven mares, from 3 to 15 years of age, were examined during the months of August and September 2004, in Brazil. Ultrasound evaluations were performed during 2 weeks before the start of the experiment to confirm transitional characteristics (no follicles larger than 25 mm and no corpus luteum [CL] present). After this period, as the mares obtained a follicle of at least 25 mm, they were assigned to one of two groups: (1) control group, untreated; (2) treated with 12.5 mg eFSH, 2 times per day, until at least half of all follicles larger than 30 mm had reached 35 mm. Follicular activity of all mares was monitored. When most of the follicles from treated mares and a single follicle from control mares acquired a preovulatory size (≥35 mm), 2,500 IU human chorionic gonadotropin (hCG) was administered IV to induce ovulation. After hCG administration, the mares were inseminated with fresh semen every other day until ovulation. Ultrasound examinations continued until detection of the last ovulation, and embryo recovery was performed 7 to 8 days after ovulation. The mares of the treated group reached the first preovulatory follicle (4.1 ± 1.0 vs 14.9 ± 10.8 days) and ovulated before untreated mares (6.6 ± 1.2 vs 18.0 ± 11.1 days; P < .05). All mares were treated with prostaglandin F_2α (PGF_2α), on the day of embryo flushing. Three superovulated mares did not cycle immediately after PGF_2α treatment, and consequently had a longer interovulatory interval (22.4 vs 10.9 days, P < 0.05). The mean period of treatment was 4.79 ± 1.07 days and 85.71% of mares had multiple ovulations. The number of ovulations (5.6 vs 1.0) and embryos (2.0 vs 0.7) per mare were higher (P < 0.05) for treated mares than control mares. In conclusion, treatment with eFSH was effective in hastening the onset of the breeding season, inducing multiple ovulations, and increasing embryo production in transitional mares. This is the first report showing the use of FSH treatment to recover embryos from the first cycle of the year.     

Efficacy of Deslorelin Acetate (SucroMate) on Induction of Ovulation in American Quarter Horse Mares

Equine clinicians rely on ovulation induction agents to provide a timed ovulation in mares for optimal breeding management. Numerous studies have been performed on the efficacy of human chorionic gonadotropin (hCG) to induce ovulation in the mare, but limited clinical data are available for the new deslorelin acetate product SucroMate. This study was designed to evaluate the efficacy of SucroMate (deslorelin) in comparison with hCG to induce ovulation. American Quarter horse mares (n = 256) presented to Colorado State University for breeding management were used in this study. Mares received either deslorelin or hCG when a follicle ≥35 mm was detected by transrectal ultrasound in the presence of uterine edema. Ultrasonographic examinations were subsequently performed once daily until ovulation was detected. Deslorelin was administered to 138 mares during168 estrous cycles, and hCG was given to 118 mares during 136 estrous cycles. Mares administered deslorelin had a similar (P < .05) higher ovulation rate (89.9%) within 48 hours following drug administration than mares administered hCG (82.8%). There are no effects of season or age on ovulation rates in either treatment group. Twenty-one mares administered deslorelin and 11 mares administered hCG were monitored by transrectal ultrasound every 6 hours to detect ovulation as part of a frozen semen management program. Average intervals from deslorelin or hCG administration to ovulation were 41.4 ± 9.4 and 44.4 ± 16.5 hours, respectively. Results of this study indicate that SucroMate is effective at inducing a timed ovulation in the mare.     

The effect of fixed-time artificial insemination protocol initiated at different stages of the estrous cycle on follicle development and ovulation in gilts

Hormonal products have been developed for fixed-time artificial insemination (FTAI) to improve the efficiency of swine production. Here, we evaluated the effect of an FTAI protocol initiated during different phases of the estrous cycle on follicle development and ovulation in gilts. A total of 36 gilts were equally divided into three groups designated as the luteal (L), follicular (F), and post-ovulation (O) groups and fed with 20 mg of altrenogest for 18 days, followed by intramuscular injection of 1000 IU PMSG at 42 h after withdrawal of altrenogest, and 100 μg of GnRH after an 80-h interval. The L group had the highest number of follicles 4–6 mm in diameter, as well as corpora hemorrhagica. The mRNA expression of caspase-9 in the L group were significantly lower than those in the O and F groups (P < 0.05), while CYP11A1 and VEGF mRNA expression levels were significantly higher (P < 0.05). Moreover, FSHR mRNA levels were significantly higher in the O group than in the L, F, and control groups (P < 0.05). LHCGR and CYP19A1 mRNA levels were the highest in the F group (P < 0.05). Thus, the changes in the expression of genes associated with follicular development, maturation, and ovulation identified in this study indicated that initiation of the FTAI protocol during the luteal phase induced a better environment for follicle development and ovulation in gilts.     

补饲与犊牛断乳对产后母牦牛发情周期恢复的影响研究

为了提高当年产犊母牦牛的发情率,我们对选定的120头怀孕母牦牛进行补饲,同时在犊牛产后3个月对犊牛进行隔离断奶,补饲试验于2010年3月初开始：100头母牦牛随机分为两组,试验组Ⅰ 50头母牦牛隔离断奶后进行同期发情和定时授精处理;Ⅱ组50头母牦牛隔离断乳.不进行同期发情处理,发情母牛进行人工授精。人工授精冻精液为荷斯坦和野牦牛冻精。配种45d后进行怀孕诊断。Ⅰ组发情39头,发情率为78%（39/50）,怀孕34头妊娠率为68%（34/50）;Ⅱ组发情31头,发情率为62%（31/50）,怀孕27头,妊娠率为54%（27/50）。相同草场放牧50头适配母牦牛作为对照。对照组母牛和犊牛不进行隔离和短期断乳;对照组发情率为12%（6/50）,妊娠率为6.32%（3/50）。试验结果表明,通过对带犊的母牦牛实施隔离断奶,能够明显提高当年产犊母牦牛的发情率和妊娠率。     

酶联免疫法检测动物源性食品中甲羟孕酮的残留

本试验旨在利用酶联免疫技术对鸡肉和鱼肉中的甲羟孕酮药物残留进行检测。经过测试,该试剂盒对鸡肉和鱼肉样本的检测限均为ug／kg;当药物添加浓度为1、2、4ug／kg时,其平均回收率范围是65．5％～94．6％,批内、批间相对标准偏差均小于10％;交叉反应率试验表明该试剂盒的特异性良好：酶联免疫法与仪器法的验证结果一致。     

Occurrence of Equine Coital Exanthema in Mares from an Embryo Transfer Center

Equine coital exanthema (ECE) is an acute, venereal disease caused by equid herpesvirus 3 (EHV-3), characterized by the formation of papules, vesicles, pustules, and ulcers on the vaginal and vestibular mucosa as well as on the skin of the penis, prepuce, and perineal region of mares and stallions. The present work describes an outbreak of ECE characterized by typical lesions around the anus and on the perineal skin, discomfort, and anorectal lymphadenopathy, which occurred in a large number of donor and recipient mares at an embryo transfer center in Argentina. We found that the horses' movement pattern, the environmental conditions, and the management procedures could have favored the introduction and/or reactivation from latency and spread of EHV-3. Although this is the first report of an outbreak of ECE in an embryo transfer facility, it reinforces the need to introduce additional hygienic and preventive measures to avoid EHV-3 spread and future ECE outbreaks.     

Age-Dependent Effect of Foal Heat Breeding on Pregnancy and Embryo Mortality Rates in Thoroughbred Mares

The aim of the present study was to evaluate the correlation of age and heat cycle to determine reproductive efficiency in young and aged Thoroughbred mares bred on foal heat (FH) or on second heat (SH) after foaling. Embryo mortality (EmbM) was determined every time a mare was found open after a positive pregnancy diagnosis. Parturition to breeding interval, pregnancy rate (PregR) and EmbM rate were the dependent variables and the treatments were breeding on the FH or on SH. The cutoff age to obtain above-average probability for the EmbM was 10 years old. PregR in mares bred on FH was lower compared with SH (P < .01); however, it was neither affected by the age of mares (P > .05) nor by the age group of mares (P > .05). Regarding FH and SH, there was a difference in PregR in young mares (P < .01), unlike in aged mares (P > .05). EmbM rate was not different between mares bred on FH or SH (P > .05) although it was affected by age of mares (P < .01). EmbM was higher in oldest than young mares (P < .01). Aged mares bred on FH had a significantly higher EmbM rate compared with the young group also bred on FH (P < .01). In conclusion, the reproductive efficiency of Thoroughbred mares bred on FH is dependent of the age. Aged mares (≥10 years old) should be bred at their SH to reduce EmbM and improve reproductive performance.     

Factors Influencing the Frequency of Pregnancy Loss among Thoroughbred Mares in Hidaka,Japan

Pregnancy loss in mares is thought to be a main problem associated with reproductive efficiency. To clarify the situation of pregnancy loss in Thoroughbred mares in Japan, the occurrence of pregnancy loss before and after 35 days of gestation was investigated with 1,476 Thoroughbred mares in Hidaka, Japan, from 2007 to 2009. Pregnancy loss on days 17-35 was determined by ultrasound examination between 17 and 35 days after the last mating. Follow-up surveys were conducted between 35 days and foaling to determine pregnancy loss on day 35 until foaling in 843 of these mares. Using multiple logistic regression analysis, we assessed the influence of mare age, reproductive status, twin pregnancy reduction, body condition score (BCS), estrus type in foaling mares (foal heat or not), progesterone therapy, and endometrial cysts on pregnancy loss rates on days 17-35 and on day 35 until foaling in this population of mares. The pregnancy loss rates on days 17-35 and on day 35 until foaling were 5.8% and 8.7%, respectively. The overall pregnancy loss rate (day 17 until foaling, including parturient losses) was 14.7%. Risk factors for pregnancy loss included decrease in BCS between 17 and 35 days, <5 BCS at day 35, mating during foal heat, and endometrial cysts. In all, 14.7% of pregnancies were lost between day 17 and birth, contributing significantly to reduced reproductive efficiency in Thoroughbred mares in Japan. These observations indicate that mares should be maintained at high BCS and should be prevented from mating in foal heat to decrease the pregnancy loss rates.     

Effects of Prostaglandin,N-methyl-D-aspartate and Letrozole on Ewes Plasma Levels of Reproductive Hormones were Evaluated on the Basis of Medroxyprogesterone Acetate Supplementation

This study was aimed to investigate the effects of the different compatibility of medroxyprogesterone acetate (MPA) with prostaglandin(PG), N-methyl-D-aspartate (NMDA) and letrozole (LE) on plasma related hormones levels of reproductive ewes. Thirty-nine and 3-year-old multiparity Suffolk ewes with average weight (75.51+11.55)kg were selected,and assigned into 3 groups,test group Ⅰ:Basis diet+34 mg/d MPA+1 mL/ewe PG, test group Ⅱ:Basis diet+34 mg/d MPA+600 mg/d NMDA, test group Ⅲ:Basis diet+34 mg/d MPA+ 14 mg/d LE, respectively, the trial period lasted for 18 days. The results showed as follows:On the basis of supplemental feeding MPA with PG treated,the levels of FSH in plasma of ewes were extremely significantly increased (P<0.01); Treated with NMDA, the levels of E₂, MLT,FSH and LH in plasma of ewes were extremely significantly increased (P<0.01), respectively;Treated with LE, the levels of MLT,LH and T in plasma of ewes were extremely significantly increased (P<0.01), respectively. This study suggested that MPA+NMDA and MPA+LE could be used as medicines for regulate and control oestrus of ewes, and the effect of MPA+NMDA was the best.     

补饲醋酸甲羟孕酮基础上分别进行前列腺素、N-甲基-D-天冬氨酸和来曲唑处理对母羊血浆繁殖激素水平的影响

试验旨在研究醋酸甲羟孕酮（medroxyprogesterone acetate,MPA）与前列腺素（prostaglandin,PG）、N-甲基-D-天冬氨酸（N-methyl-D-aspartate,NMDA）和来曲唑（letrozole,LE）的不同配伍对母羊血浆繁殖相关激素水平的影响。选取3岁经产萨福克母羊39只,平均体重（75.51±11.55） kg,随机均分为3组,试验Ⅰ组饲喂基础日粮+34 mg/（d·只） MPA+1 mL/只PG,试验Ⅱ组饲喂基础日粮+34 mg/（d·只） MPA+600 mg/（d·只） NMDA,试验Ⅲ组饲喂基础日粮+34 mg/（d·只） MPA+14 mg/（d·只） LE,试验期18 d。结果发现,补饲MPA基础上进行PG处理,母羊血浆中FSH水平呈极显著升高（P<0.01）;补饲MPA基础上进行NMDA处理,母羊血浆中E2、MLT、FSH和LH水平均呈极显著升高（P<0.01）;补饲MPA基础上进行LE处理,母羊血浆中MLT、LH和T水平均呈极显著升高（P<0.01）。综合比较各生殖激素之间的关系及变化规律,在本试验条件下,建议MPA与NMDA和LE分别结合使用,可作为调控母羊繁殖性能的药品;且通过比较激素水平得出,MPA与NMDA组合效果最佳。     

Metabolism of Methenolone Acetate in a Veal Calf

The use of anabolic steroids has been banned in the European Union since 1981. In this study, the metabolism of the anabolic steroid methenolone acetate, was investigated in a male veal calf. After daily oral administration of methenolone acetate, three main metabolites were detected in both urine and faeces samples. Among these metabolites, α-methenolone was apparently the main one, but 1-methyl-5α-androstan-3,17-diol and 3α-hydroxy-1-methyl-5α-androstan-17-one were also observed. The parent compound was still detectable in faeces. As a consequence, abuse of methenolone acetate as growth promoter can be monitored by analysing urine and faeces samples. A few days after the last treatment, however, no metabolites were observed. α-Methenolone was detectable in urine until 5 days after the last treatment, but in faeces no metabolites were detectable after 3 days.     

Metabolomic Profile of Allantoic and Amniotic Fluid in Late-term Gestational Mares Characterized by 1H-nuclear Magnetic Resonance Spectroscopy

The amniotic and allantoic fluid compartments in the mare serve essential roles throughout pregnancy and parturition. Although the global metabolomic profile of amniotic fluid in women has been extensively characterized, current data for equine fetal fluids are limited. Therefore, the goal of this study was to characterize the global metabolomic profile of equine allantoic and amniotic fluid through nuclear magnetic resonance spectroscopy. Fetal fluids were collected between 270 and 295 days of gestation from 12 pregnancies through ultrasound-guided transabdominal puncture. A total of 24 samples (n = 10 allantoic fluid; n = 9 amniotic fluid; n = 5 admixed fluid) were analyzed by one-dimensional proton (¹H) and two-dimensional (¹H-¹³ C) nuclear magnetic resonance spectroscopy. Metabolites were integrated and compared between fluid types using a Kruskal–Wallis test at P < .05 significance. A total of 28 distinct metabolites were found in allantoic and admixed fluid, whereas 23 metabolites were identified in amniotic fluid. Allantoic fluid contained significant elevations (P < .05) in the metabolites betaine, creatine, creatinine, citrate, histidine, nitrophenol, tryptophan, π-methylhistidine, and unknown metabolite #1 compared with amniotic fluid, whereas amniotic fluid contained statistically increased concentrations of the metabolite lactate compared with allantoic fluid (P = .003).